Pharmacokinetics of intra‐articular buprenorphine in horses with lipopolysaccharide‐induced synovitis

• Published in: Journal of veterinary pharmacology and therapeutics 2023-07, Vol.46 (4), p.229-237
• Main Authors: Castro‐Cuellar, Gabriel, Cremer, Jeannette, Queiroz‐Williams, Patricia, Knych, Heather K., Leise, Britta S.
• Format: Article
• Language: English
• Subjects: buprenorphine; horse; intra‐articular; lipopolysaccharide; pharmacokinetics; synovitis
• ISSN: 0140-7783; 1365-2885
• DOI: 10.1111/jvp.13119

The objective of this study was to describe the pharmacokinetics of intra‐articular (IA) administered buprenorphine in horses with lipopolysaccharide (LPS)‐induced synovitis. Radiocarpal synovitis was induced in six healthy adult horses with the IA injection of LPS (0.5 ng/joint) on two occasions in a randomized cross‐over design. Treatments (IA buprenorphine (IAB) at 5 μg/kg plus intravenous saline; and intravenous buprenorphine (IVB) at 5 μg/kg plus IA saline) were administered 4 h following LPS injection. Concentrations of buprenorphine were assessed in plasma and synovial fluid (SF) at 0.5, 2, 6, 12, and 24 h after administration. Pharmacokinetic parameters after IVB and IAB in plasma and synovial fluid were calculated using a nonlinear mixed effects model. IAB was detectable in SF of all horses at 24 h [median concentration of 6.2 (3.46–22.6) ng/mL]. IAB resulted in a median plasma concentration of 0.59 (0.42–1.68) ng/mL at 0.5 h and was detectable in all subjects for up to 6 h and in two horses for up to 12 h. IVB resulted in SF concentrations detected up to 6 h in all horses [median concentration of 0.12 (0.07–0.82) ng/mL]. Results suggest that IA buprenorphine remains present in the inflamed joint for at least 24 h and systemic absorption occurs.